This observational study reviewed the relationship between testosterone replacement therapy (TRT) and prostate cancer risk, concluding that while TRT restores androgen levels in hypogonadal men, it does not increase prostate cancer risk beyond that of the general population. Men with androgen deficiency typically have reduced prostate volume and lower PSA
This observational study examined the effects of testosterone replacement therapy (TRT) on prostate-specific antigen (PSA) levels and prostate cancer risk in hypogonadal men. The results showed that TRT significantly increased PSA levels, but there was no observed increase in prostate cancer incidence compared to the general population. These findings suggest
This observational study evaluated the safety of testosterone replacement therapy (TRT) in 31 men with symptomatic hypogonadism after undergoing brachytherapy for early-stage prostate cancer. Over a median follow-up of 5 years post-brachytherapy, TRT increased median testosterone levels from 188 ng/dL to 498 ng/dL without causing biochemical recurrence. No patients experienced
This review examines the relationship between testosterone replacement therapy (TRT) and prostate cancer risk, noting that while androgens promote prostate cancer growth in experimental models, there is no conclusive evidence linking higher testosterone levels to increased prostate cancer risk in humans. Studies have shown that TRT does not increase prostate
This review examines the benefits and misconceptions surrounding testosterone deficiency (hypogonadism) and testosterone replacement therapy (TRT). It highlights the significant health risks associated with testosterone deficiency, such as sexual dysfunction, bone loss, and metabolic syndrome, and argues that TRT can provide substantial benefits, including improved sexual function, overall well-being, and
This study examines the relationship between testosterone therapy and cancer risk, particularly its impact on prostate cancer. The findings suggest that testosterone therapy does not increase the risk of prostate cancer recurrence, even in men with high-risk prostate cancer. However, due to the retrospective nature of this and prior studies,
